Nucleic acid and corresponding protein entitled 24p4c12 useful in treatment and detection of cancer
CA 2503346 C · Owner: Agensys, Inc. · Inventors: Raitano, Arthur B.; Morrison, Karen Jane Meyrick; Jakobovits, Aya
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A novel gene 024P4C12 (also designated 24P4C12) and its encoded protein and , variants , thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult , tissue, and is aberrantly expressed in cancers. Consequently 24P4C12 provides , a diagnostic, prognostic prophylactic and/or therapeutic target for cancer. The 24P4C12 gene or fragment , thereof, or its encoded protein or variants thereof, or a fragment thereof can be used to elicit a , humoral or cellular immune response; antibodies or T cells reactive with 24P4C12 can be used in , active or passive immunization.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 27, 2002 and granted March 18, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 27, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 27, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.